Company Profile

Likarda LLC
Profile last edited on: 3/22/2024      CAGE: 6U7A1      UEI: C9WYEGN84NZ7

Business Identifier: Improving efficacy of cellular therapies
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

10330 Hickman Mills Drivw
Kansas City, MO 64137
   (816) 605-6440
Location: Multiple
Congr. District: 05
County: Jackson

Public Profile

With facilities in Cambridge MA and in Kansas City, MO., Liakada is enabling technologies to transform the way cell therapies are delivered and optimized - with the goal being to provide patients with sustainable reversal for their chronic or fatal diseases. Likarda is a several years established (2012) biotech company employing revolutionary methods to coat cells with stealth hydrogels. Called Core Shell Spherification® (CSS), these coatings protect cells from destruction, keeping them viable while maintaining them in the intended location within the body. Likarda has developed a library of 50+ different hydrogel formulations that work with Core Shell Spherification® - effectively yielding the ability uniquely to tailor coating molecules to the specific requirements of the therapeutic cells themselves. From durable and long-term coatings to degradable coatings that deliver cells over days, weeks, or months, the firm is able to create exclusive hydrogel formulations tailored for each therapeutic application. The principals had orginally developed the 3D cell culture platform at the University of Kansas Medical Center where they focused on discovering and providing next-generation treatments for diabetes. The founders discovered the power of miniaturized islets, called Kanslets™, for secondary drug testing and have published multiple studies in support of the technology. It should be noted that Likarda started out as a contract research organization, conducting research for others: large international pharmaceutical companies down to small startups. The principals were among the first able to screen for new drugs using 3D clusters of cells in a high throughput format. Revenues from the contract research were re-invested back into Likarda’s R&D programs for the firm's own cell therapy technologies. Eventually their advanced cell therapy platforms demanded the company’s full attention and the pivot was made from contract research efforts to creating new encapsulation approaches for cell therapies being developed by Likarda and by outside company partners.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Lisa A Stehno-Bittel -- President & Founder

  Stella Vnook -- Chief Executive Officer

  Stephen Harrington -- Director of Cell and Hydrogel Formulation

  Francis Karanu -- Director Of Cell Therapy R&D

  Donald Muathe -- Qa Supervisor and Sr. Analytical Chemist

  Karthik Ramachandran -- Chief Operating Officer and Co-Founder

  Joe Suarez -- Chief Financial Officer

  Aldyn Wildey -- R&D Scientist And Lab Supervisor

Company News

There are no news available.